8-K: Fortress Biotech Announces 2024 Financial Results and Corporate Updates, Including FDA Approvals and Strategic Acquisition

Fortress Biotech reports its 2024 financial results, highlighting FDA approvals for Emrosi and UNLOXCYT, the accepted New Drug Application for CUTX-101, and the acquisition of Checkpoint Therapeutics by Sun Pharma.

Summary

• Fortress Biotech announced its financial results for the year ended December 31, 2024, along with recent corporate highlights.
• The company reported consolidated net revenue of $57.7 million for the year, including $55.1 million from marketed dermatology products.
• This compares to $84.5 million in net revenue for 2023, which included $59.7 million from dermatology products.
• Consolidated net loss attributable to common stockholders was $(55.9) million, or $(2.69) per share, compared to a net loss of $(68.7) million, or $(8.47) per share in 2023.
• As of December 31, 2024, Fortress had $57.3 million in cash and cash equivalents.
• Key developments include the FDA approval of Emrosi for rosacea and UNLOXCYT for cutaneous squamous cell carcinoma.
• Checkpoint Therapeutics, a Fortress subsidiary, is set to be acquired by Sun Pharma, with Fortress expecting to receive approximately $28 million at closing, plus a 2.5% royalty on net sales of UNLOXCYT, and up to an additional $4.8 million if a contingent value right (CVR) is achieved.
• The FDA accepted the New Drug Application for CUTX-101 for Menkes disease with a PDUFA goal date of September 30, 2025.
• The commercial launch of Emrosi is underway, with initial distribution ongoing and first prescriptions filled.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss and a decrease in revenue, it also achieved significant milestones such as FDA approvals and a strategic acquisition. The future outlook is cautiously optimistic.

Positives

• FDA approval of Emrosi for rosacea provides a new treatment option and potential revenue stream.
• FDA approval of UNLOXCYT for cutaneous squamous cell carcinoma enhances the value of Checkpoint Therapeutics.
• The acquisition of Checkpoint Therapeutics by Sun Pharma provides Fortress with a significant upfront payment and potential future royalties.
• Acceptance of the New Drug Application for CUTX-101 with priority review accelerates the potential approval for Menkes disease treatment.
• The commercial launch of Emrosi is underway, indicating progress in monetizing approved products.
• Fortress reduced its total debt by entering into a new loan agreement maturing in July 2027 with funds managed by Oaktree Capital Management, L.P.

Negatives

• Consolidated net revenue decreased from $84.5 million in 2023 to $57.7 million in 2024.
• The company reported a consolidated net loss attributable to common stockholders of $(55.9) million for 2024.
• Cash and cash equivalents decreased by $23.6 million for the full year.
• The Board of Directors paused the payment of dividends on the Company's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.

Risks

• The company's growth strategy relies on acquiring and advancing assets, which carries inherent risks.
• Fortress needs substantial additional funds, and uncertainties exist regarding future financings.
• The acquisition of Checkpoint by Sun Pharma is subject to closing conditions and regulatory approvals.
• The company faces risks related to clinical testing, regulatory approvals, and commercialization of products.
• Competition and intellectual property matters pose ongoing challenges.

Future Outlook

Fortress is focused on the September 30, 2025 PDUFA goal date for CUTX-101, expects continued revenue growth from Emrosi, and anticipates additional monetization opportunities from its pipeline.

Management Comments

• Lindsay A. Rosenwald, M.D., Fortress Chairman, President and Chief Executive Officer, said, 'The fourth quarter of 2024 was transformational for Fortress, marked by two FDA approvals Emrosi and UNLOXCYT as well as the FDAs recent acceptance of the New Drug Application for CUTX-101.'
• Dr. Rosenwald continued, 'Looking ahead, we are focused on our next key milestone: the September 30, 2025, Prescription Drug User Fee Act (PDUFA) goal date for CUTX-101.'

Industry Context

The announcement reflects the ongoing trend of pharmaceutical companies focusing on acquiring and advancing assets to enhance long-term shareholder value. The acquisition of Checkpoint by Sun Pharma highlights the value of FDA-approved products and the potential for smaller biotechs to be acquired by larger pharmaceutical companies with established commercial organizations.

Comparison to Industry Standards

• Journey Medicals net product revenues for the full year ended December 31, 2024, were $55.1 million, compared to net product revenues of $59.7 million for the full year ended December 31, 2023.
• The company's R&D expenses were $56.6 million, compared to $101.7 million in the previous year, indicating a shift in investment strategy or project prioritization.
• The acquisition of Checkpoint Therapeutics by Sun Pharma is similar to other acquisitions in the biopharmaceutical industry, such as Pfizer's acquisition of Arena Pharmaceuticals, where larger companies acquire smaller companies with promising drug candidates.

Stakeholder Impact

• Shareholders may benefit from the acquisition of Checkpoint Therapeutics and potential future royalties.
• Patients may benefit from new treatment options such as Emrosi and UNLOXCYT.
• Employees may experience changes due to the acquisition of Checkpoint Therapeutics.

Next Steps

• Completion of the acquisition of Checkpoint Therapeutics by Sun Pharma in the second quarter of 2025.
• Potential FDA approval of CUTX-101 with a PDUFA goal date of September 30, 2025.
• Continued commercialization of Emrosi and pursuit of additional monetization opportunities.

Key Dates

Keywords

Fortress Biotech, Financial Results, FDA Approval, Emrosi, UNLOXCYT, CUTX-101, Checkpoint Therapeutics, Sun Pharma, Acquisition, Rosacea, Cutaneous Squamous Cell Carcinoma, Menkes Disease, Biopharmaceutical